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ABSTRACT
Objectives  Synovial ﬁ  broblasts and osteoblasts 
generate active glucocorticoids by means of the 
11β-hydroxysteroid dehydrogenase type 1 (11β-
HSD1) enzyme. This activity increases in response to 
proinﬂ  ammatory cytokines or glucocorticoids. During 
inﬂ  ammatory arthritis synovium and bone are exposed 
to both these factors. This study hypothesised that 
glucocorticoids magnify the effects of inﬂ  ammatory 
cytokines on local glucocorticoid production in both 
synovium and bone.
Methods  The effects of inﬂ  ammatory cytokines (IL-1β/
tumour necrosis factor alpha; TNFα) and glucocorticoids, 
alone or combined, were assessed on the expression 
and activity of 11β-HSD1 in primary synovial ﬁ  broblasts, 
primary human osteoblasts and MG-63 osteosarcoma 
cells. A range of other target genes and cell types were 
used to examine the speciﬁ  city of effects. Functional 
consequences were assessed using IL-6 ELISA.
Results  In synovial ﬁ  broblasts and osteoblasts, 
treatment with cytokines or glucocorticoids in isolation 
induced 11β-HSD1 expression and activity. However, 
in combination, 11β-HSD1 expression, activity and 
functional consequences were induced synergistically to 
a level not seen with isolated treatments. This effect was 
seen in normal skin ﬁ  broblasts but not foreskin ﬁ  broblasts 
or adipocytes and was only seen for the 11β-HSD1 gene. 
Synergistic induction had functional consequences on IL-6 
production.
Conclusions  Combined treatment with inﬂ  ammatory 
cytokines and glucocorticoids synergistically induces 11β-
HSD1 expression and activity in synovial ﬁ  broblasts and 
osteoblasts, providing a mechanism by which synovium 
and bone can interact to enhance anti-inﬂ  ammatory 
responses by increasing localised glucocorticoid levels. 
However, the synergistic induction of 11β-HSD1 might 
also cause detrimental glucocorticoid accumulation in 
bone or surrounding tissues.
Inﬂ  ammatory joint disease is associated with focal 
bone loss, periarticular osteopenia and generalised 
osteoporosis. Bone loss is associated with uncou-
pling of bone resorption from formation but the 
basis for this is poorly understood.1 2 Systemic 
bone loss in other inﬂ  ammatory diseases is exag-
gerated by treatment with therapeutic gluco-
corticoids.3 How inﬂ  ammation sensitises bone to 
glucocorticoids is unknown. We have previously 
shown that synovial ﬁ   broblasts and osteoblasts 
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generate active glucocorticoids through the expres-
sion of 11β-hydroxysteroid dehydrogenase type 1 
(11β-HSD1).4–7 This enzyme converts inactive 
glucocorticoids (cortisone and prednisone) to 
their active counterparts (cortisol and predniso-
lone). This activity increases in vitro in response to 
proinﬂ  ammatory cytokines or glucocorticoids.4 5 8 
Glucocorticoid generating capacity in synovial 
tissue correlates with the erythrocyte sedimenta-
tion rate in patients with inﬂ  ammatory arthritis.6 
Systemic measures of 11β-HSD1 activity also pre-
dict the effect of therapeutic glucocorticoids on 
bone markers in healthy men.9 However, in clini-
cal situations both proinﬂ  ammatory cytokines and 
glucocorticoids are likely to impact on 11β-HSD1 
expression but the effect of these factors in combi-
nation is unclear. Typically, glucocorticoids inhibit 
proinﬂ  ammatory cytokine signalling10 but the pres-
ence of high 11β-HSD1 activity in inﬂ  amed joints 
despite high glucocorticoid levels suggested that 
glucocorticoids fail to suppress the effect of pro-
inﬂ  ammatory cytokines on 11β-HSD1. We exam-
ined this hypothesis in primary synovial ﬁ  broblasts 
and osteoblasts. We found that 11β-HSD1 expres-
sion and activity increased dramatically in response 
to the combination of inﬂ  ammatory cytokines and 
glucocorticoids. This induction was speciﬁ  c  for 
11β-HSD1, did not occur in foreskin ﬁ  broblasts 
or adipocytes, and had functionally important 
effects.
METHODS
Cell culture
Reagents were obtained from Sigma (Poole, UK) 
unless stated. Primary synovial ﬁ  broblasts were gen-
erated from synovial tissue obtained from patients 
with rheumatoid arthritis (by 1987 American 
Rheumatism Association classiﬁ  cation  criteria) 
during knee arthroplasty as described.4 Isolated 
ﬁ  broblasts were grown in RPMI-1640 medium con-
taining 1% (v/v) non-essential amino acids (NEAA), 
1% penicillin/streptomycin, 1% sodium pyruvate, 
2mM glutamine and 20% fetal bovine serum (FBS; 
Labtech, Sussex, UK). Hs-68 cells, a primary cul-
ture of human foreskin ﬁ  broblasts, were cultured 
in Dulbecco’s modiﬁ  ed Eagle’s medium (DMEM) 
with 20% FBS and 2mM glutamine.
Primary human osteoblasts were cultured from 
bone chips obtained at orthopaedic surgery as 
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described.8 Trabecular bone was treated with 2% type 1 colla-
genase for 2 h, washed then cultured in DMEM/F12 containing 
10% FBS, 1% NEAA and 2 mmol/litre glutamine. MG-63 cells 
were cultured in minimal essential medium with 10% FBS, 1% 
NEAA and 2 mmol/litre glutamine. SV-HFO cells were cultured in 
α minimal essential medium (Gibco, Paisley, UK) with 20 mmol/
litre HEPES, pH 7.5, streptomycin/penicillin, 1.8 mmol/l calcium 
chloride, 2% FBS and 10 mmol/litre β-glycerophosphate.
Chub-S7 cells, a human pre-adipocyte cell line, were cul-
tured in DMEM/F12 with 10% FBS to maintain a preadipocyte 
phenotype. Treatment with DMEM/F12 with 10% FBS, 17μM 
D-panthotenic acid, 33μM biotin, 1nM triiodothyronine, 166nM 
insulin, 1μM cortisol and 1μM GW1929 was used to generate 
mature adipocytes. Patients gave informed consent and the 
study had Local Research Ethics Committee approval.
Cells were cultured with proinﬂ  ammatory cytokines (IL-1β/
tumour necrosis factor alpha (TNFα); 0.1–10 ng/ml) and gluco-
corticoids (cortisol/dexamethasone; 1–100 nM) alone or in 
combination.
RNA extraction and real-time PCR
RNA was extracted using TRI reagent (Sigma). Aliquots (1 μg) 
were reverse transcribed using random hexamers (Promega, 
Madison, Wisconsin, USA).5 The expression of messenger 
RNA for 11β-HSD1, 11β-HSD2, GRα, GRβ, osteoprotegerin 
and cyclooxygenase-2 was assessed using real-time PCR using 
an ABI7500 system (Applied Biosystems, Warrington, UK) with 
18S as internal reference. Reactions contained TaqMan PCR 
mastermix, 500–900 nmol primers, 100–200 nmol TaqMan 
probe and 25–50 ng complementary DNA. Data were obtained 
as Ct values and used to determine ΔCt values (Ct target – Ct 
18S). Fold-change in expression was determined by subtract-
ing ΔCt values for treated cells from their control. The resulting 
ΔΔCt values were used to calculate fold-change using the equa-
tion 2ΔΔCt. Probe and primer sequences were as follows: 11β-
HSD1, forward primer AGGAAAGCTCATGGGAGGACTAG, 
reverse ATGGTGAATATCATCATGAAAAAGATTC, probe 
CATGCTCATTCTCAACCACATCACCAACA; GRα, 
forward AACTGGCAGCGGTTTTATCAACT, reverse 
AATACTCATGGTCTTATCCAAAAATGTTT, probeAT-
TCTATGCATGAAGTGGTGGAAAATCTCCTTAACT-
ATTG; GRβ forward AACTGGCAGCGGTTTTATCAACT, 
reverse TGTGTGAGATGTGCTTTCTGGTT, probe 
AACTCTTGGATTCTATGCATGAAAATGTTATGTGGTTA. 
TaqMan assays for osteoprotegerin (Hs00171068_m1) and 
cyclooxygenase-2 (Hs00153133_m1) were from Applied 
Biosystems.
Western blot analysis
The expression of 11β-HSD1 protein was determined by west-
ern blotting using a speciﬁ  c 11β-HSD1 antibody (Binding Site, 
UK).11 Expression was analysed relative to β-actin. Densitometry 
was performed on three separate experiments using primary 
synovial ﬁ  broblasts from three different individuals.
11β-HSD enzyme activity assays
Conﬂ  uent cells were cultured in medium containing 100 nM 
cortisone (to measure oxo-reductase/activation activity) or cor-
tisol (dehydrogenase/inactivation activity) along with tritiated 
tracer. Steroids were extracted using dichloromethane and sepa-
rated by thin-layer chromatography using ethanol:chloroform 
(8:92) as the mobile phase. Thin-layer chromatography plates 
were analysed by Bioscan imager (Bioscan, Washington, DC, 
USA) and the fractional conversion of steroids was calculated. 
The protein concentration was assessed by a 96-well assay kit 
(Bio-Rad, Hercules, California, USA). Results were expressed as 
pmol product/h per milligram of protein and experiments were 
performed in triplicate.
Functional consequences of induction of 11β-HSD1 activity on 
IL-6 production
Primary ﬁ  broblasts were incubated with no treatment, 10 ng/ml 
IL-1β, 100 nmol/litre dexamethasone or both for 24 h. Medium 
was then changed to fresh medium without cytokines or gluco-
corticoids and left for 24 h. Cells were then treated for 24 h 
with or without 100 nmol/litre cortisone and media collected. 
Soluble IL-6 was measured by sandwich ELISA (BD Biosciences, 
Torreyana, San Diego, California, USA). Data were expressed as 
the production of IL-6 in pg/well.
Statistics
Data were reported as mean±standard error (SE) of replicate 
mean values. One-way and two-way analysis of variance analy-
ses with Tukey post-hoc test were performed using SPSS Data 
Editor and SigmaStat software.
RESULTS
Inﬂ  ammatory cytokines and glucocorticoids synergistically 
induce 11β-HSD1 expression and activity in synovial ﬁ  broblasts
As previously reported, when used in isolation, pro-inﬂ  amma-
tory cytokines (IL-1β/TNFα) and glucocorticoids increased 11β-
HSD1 mRNA expression and oxidoreductase enzyme activity 
in primary human synovial ﬁ  broblasts (ﬁ  gure 1A,B). However, 
the combination of IL-1β and glucocorticoids substantially 
increased 11β-HSD1 mRNA levels and enzyme activity relative 
to either individual treatment. This pattern of activity was con-
sistently seen in cells from three separate donors and data reﬂ  ect 
the combined results from these three patients. In keeping with 
our previous report, no dehydrogenase activity was detectable 
in these cells.4 Western blotting using extracts from primary 
synovial ﬁ   broblasts showed that this change was caused by 
increased 11β-HSD1 protein expression (ﬁ  gure 1C).
Inﬂ  ammatory cytokines and glucocorticoids synergistically 
induce 11β-HSD1 in osteoblasts
The same pattern of induction of 11β-HSD1 mRNA and enzyme 
activity was also observed in primary human osteoblasts and 
MG63 cells (ﬁ  gure 2A,B). Similar results were obtained using 
TNFα as co-treatment (for MG-63 cells increases in mRNA 
expression relative to untreated cells: 54-fold with 10 ng/ml 
TNFα; 19-fold with 100 nM dexamethasone; 2952-fold with 
combined TNFα/dexamethasone), or when using cortisol as 
  co-treatment (increases in mRNA expression: 12-fold with 100 
nM cortisol; 1150-fold with combined TNFα/cortisol).
Synergistic response to inﬂ  ammatory cytokines and 
glucocorticoids is speciﬁ  c for 11β-HSD1
Analyses using primary synovial ﬁ  broblasts conﬁ  rmed that a 
synergistic effect of co-treatment with IL-1β and dexametha-
sone was not observed for other glucocorticoid signalling com-
ponents such as GRα/β (ﬁ  gure 2C). Moreover, analysis of two 
cytokine gene targets, osteoprotegerin and cyclooxygenase-2, 
showed that although the expression of both was increased fol-
lowing IL-1β treatment, this effect was abrogated rather than 
potentiated in combination with dexamethasone (ﬁ  gure 2C).
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IL-1β and dexamethasone in isolation had a small impact on 
11β-HSD1 mRNA expression, but the effect of the combination 
was less than either treatment alone. This indicates that syner-
gistic interactions are not universal in cells expressing 11β-HSD1 
activity or of stromal origin.
Synergistic induction of 11β-HSD1 varies with osteoblast 
differentiation
To investigate whether the synergistic induction of 11β-HSD 
in osteoblasts occurs at speciﬁ  c stages of osteoblast differen-
tiation, we assessed the effects of IL-1β and dexamethasone 
on 11β-HSD1 expression in SV-HFO human fetal osteoblasts. 
In previous studies we showed that cells readily express 11β-
HSD1 mRNA and enzyme activity when cultured without 
Synergistic induction of 11β-HSD1 expression occurs in a 
limited number of cell types
The effects of IL-1β and dexamethasone were examined in 
other cell types. A synergistic effect on 11β-HSD1 expression 
was seen in primary skin ﬁ  broblasts isolated from the patients 
from whom synovial ﬁ  broblasts were generated (ﬁ  gure 3A). This 
effect was not, however, observed in Hs68 primary ﬁ  broblasts 
derived from foreskin. Adipocytes and preadipocytes express 
11β-HSD1, and expression is increased by pro-  inﬂ  ammatory 
cytokines or glucocorticoids.12 13 The effect of treatments in iso-
lation or combination was examined in Chub-S7 human differ-
entiating adipocytes (ﬁ  gure 3A). Glucocorticoid treatment alone 
induced 11β-HSD1 expression in undifferentiated cells with 
no effect of IL-1β or any additional effect of IL-1β in combina-
tion with dexamethasone evident. In differentiated adipocytes, 
Figure 1  Synergistic induction of 11β-hydroxysteroid dehydrogenase 
type 1 (11β-HSD1) mRNA, activity and protein expression in synovial 
ﬁ  broblasts by inﬂ  ammatory cytokines and glucocorticoids. (A) Effect 
of 10 ng/ml IL-1β/tumour necrosis factor alpha (TNFα), 100nM 
dexamethasone (DEX) or combined IL-1β/TNFα and dexamethasone 
on the expression of 11β-HSD1 mRNA expression as determined by 
real-time reverse transcriptase PCR. *p<0.05, **p<0.01 compared 
with control (Con); #p<0.05 compared with single treatments. Data 
are based on cultures from three individuals. (B) Effect of 10 ng/ml 
IL-1β/TNFα, 100nM dexamethasone or combined IL-1β/TNFα and 
dexamethasone on 11β-HSD1 catalysed synthesis of 3H-cortisol from 
3H-cortisone (oxo-reductase activity) as determined by scanning thin-
layer chromatography. Data are shown as pmoles/h per milligram of 
protein and are based on cultures from three individuals. (C) Effect of 
IL-1β, dexamethasone or combined IL-1β/dexamethasone on 11β-
HSD1 protein expression in primary cultures of synovial ﬁ  broblasts 
as determined by western blotting. Expression is relative to β-actin. 
Densitometry data reﬂ  ect expression in three separate primary cultures 
of synovial ﬁ  broblasts derived from different patients.
Figure 2  Synergistic induction of 11β-hydroxysteroid dehydrogenase 
type 1 (11β-HSD1) mRNA and activity in human osteoblastic cell culture 
models by inﬂ  ammatory cytokines and glucocorticoids. (A) Effect of 
10 ng/ml IL-1β, 100nM dexamethasone (DEX) or combined IL-1β/
dexamethasone on the expression of 11β-HSD1 mRNA in primary 
human osteoblasts and MG-63 cells as determined by real time reverse 
transcriptase PCR. Data are normalised for 18S rRNA expression and are 
shown as fold-change relative to an arbitrary value of one for vehicle-
only control cells (Con). *p<0.05, **p<0.01 compared with control; 
#p<0.05 compared with single treatments, N=3. (B) Effect of 10 ng/
ml IL-1β, 100nM dexamethasone and combined IL-1β/dexamethasone 
on 11β-HSD1 catalysed synthesis of 3H-cortisol from 3H-cortisone (oxo-
reductase activity) by primary human osteoblasts and MG-63 cells as 
determined by scanning thin-layer chromatography. Data are shown as 
pmoles/h per milligram of protein, N=3. (C) Effects of combined IL-1β and 
dexamethasone on expression of mRNA for GRα, GRβ, osteoprotegerin 
(OPG) and cyclooxygenase-2 (COX-2) in primary synovial ﬁ  broblasts 
demonstrating that synergism is speciﬁ  c for the induction of 11β-HSD1 
expression. Data are based on cultures from three individuals.
0
200
400
600
800
1000
1200
1400
1600
0
0.5
1
1.5
0
100
200
300
400
500 Primary 
osteoblasts
0
0.5
1
1.5
2
2.5
3
MG-63 
cells
0
0.5
1
1.5
2
2.5 **
**
** #
**
**
** #
** **
AB
Con        IL-1β DEX     IL-1β+DEX Con         IL-1β DEX     IL-1β+DEX
C
o
r
t
i
s
o
l
 
g
e
n
e
r
a
t
i
o
n
 
p
m
o
l
/
m
g
/
h
r
Con        IL-1β DEX     IL-1β+DEX
F
o
l
d
 
c
h
a
n
g
e
 
i
n
 
1
1
β
-
H
S
D
1
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
Con         IL-1β DEX     IL-1β+DEX
0
0.5
1
1.5
2
0
5
10
15
20
25
30
0
2
4
6
8
OPG COX-2
F
o
l
d
 
c
h
a
n
g
e
 
i
n
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
p
r
i
m
a
r
y
 
 
s
y
n
o
v
i
a
l
 
f
i
b
r
o
b
l
a
s
t
s
GRα
** **
Con        IL-1β DEX     IL-1β+DEX
Con        IL-1β DEX     IL-1β+DEX Con         IL-1β DEX     IL-1β+DEX
Con         IL-1β DEX     IL-1β+DEX
C
Primary 
osteoblasts
MG-63 
cells
* #
GRβ
43_annrheumdis107466.indd   1187 43_annrheumdis107466.indd   1187 5/6/2010   7:14:15 PM 5/6/2010   7:14:15 PMExtended report
Ann Rheum Dis 2010;69:1185–1190. doi:10.1136/ard.2009.107466 1188
expression when cells were co-treated with IL-1β for 24 h (data 
not shown).
Dose response and time course of 11β-HSD1 induction
Dose-dependency studies of MG-63 cells indicated that syner-
gistic interaction between IL-1β and dexamethasone occurred at 
all tested concentrations of IL-1β (ﬁ  gure 4A). Synergistic induc-
tion of 11β-HSD1 was also seen across a range of concentra-
tions of dexamethasone (1–100 nM; data not shown). The effect 
of combined IL-1β with dexamethasone compared with IL-1β 
alone was seen at 8 h, and the difference was most dramatic 
at 24–48 h (ﬁ  gure 4B, expression of dexamethasone alone not 
shown because the relative expression was very low).
Functional impact of synergistic induction of 11β-HSD1 activity 
in primary ﬁ  broblasts
The functional impact of the synergistic induction of 11β-HSD1 
activity was examined in synovial ﬁ  broblasts treated with IL-1β, 
dexamethasone or a combination of IL-1β and dexamethasone 
for 24 h followed by 24 h without treatment (washout period). 
Cells were then cultured for 24 h with or without 100 nM corti-
sone before media were removed for the analysis of IL-6 levels. 
Under these conditions the addition of IL-1β or dexametha-
sone in isolation did not signiﬁ  cantly sensitise cells to cortisone 
  (ﬁ  gure 5). However, cells treated with the combination of IL-1β 
and dexamethasone were markedly responsive to cortisone, as 
evidenced by a signiﬁ  cant reduction in IL-6 production.
gluco  corticoids, and that this activity aids the mineralisation of 
mature cultures. However, when treated with 100 nM dexa-
methasone, cells lose the expression of 11β-HSD1, suggesting 
that this pathway becomes redundant in the presence of exoge-
nous dexamethasone.14 15 Data in ﬁ  gure 3B conﬁ  rmed previously 
reported observations, that cells show an increase in 11β-HSD1 
expression between days 7 and 14 of culture, with a subsequent 
decline at day 21. In cells with low 11β-HSD1 expression (days 
7 and 21 cultures) treatment with either IL-1β (10 ng/ml) or 
dexamethasone (100 nM) for the last 24 h of culture induced 
the expression of 11β-HSD1. As with other osteoblast mod-
els, this response was enhanced when IL-1β and dexametha-
sone were added together. Cells at day 14 did not show altered 
11β-HSD1 expression with single or combined treatments, but 
basal expression was already as high as the maximal expres-
sion seen at other times with combined treatments. SV-HFO 
cells exposed to continual dexamethasone treatment showed 
suppressed 11β-HSD1 expression at all time points but high 
Figure 3  Synergistic effect of IL-1β and dexamethasone (DEX) is 
restricted to ﬁ  broblasts and osteoblasts and depends on the stage 
of osteoblast differentiation. (A) Effects of combined IL-1β and 
dexamethasone on the expression of mRNA for 11β-hydroxysteroid 
dehydrogenase type 1 (11β-HSD1) in primary skin ﬁ  broblasts, foreskin 
ﬁ  broblasts, undifferentiated and differentiated adipocytes. *p<0.05 
and **p<0.01 compared with control (Con); #p<0.05 compared with 
single treatments, N=3. (B) Synergistic induction of 11β-HSD1 occurs 
at different stages of osteoblast differentiation. Human osteoblastic 
SV-HFO cells were cultured for 7, 14 or 21 days under the following 
conditions: control cells (vehicle); cells + 10 ng/ml IL-1β; cells + 
dexamethasone for 24 h; cells + IL-1β + dexamethasone for 24 h. At 
each time point RNA was isolated for real-time reverse transcriptase 
PCR analysis. Data are shown as the mean±SE fold-induction in 11β-
HSD1 mRNA expression relative to day 7 cells. **p<0.01 compared 
with untreated control at each time point; #p<0.05 compared with 
single treatments, N=6.
Figure 4  Dose response and time course of 11β-hydroxysteroid 
dehydrogenase type 1 (11β-HSD1) induction. (A) Dose-response effects 
of 10 ng/ml IL-1β, 100 nM dexamethasone (DEX) and combined IL-1β 
and dexamethasone on 11β-HSD1 mRNA expression in MG-63 cells. 
Combined treatment at 0.1 ng/ml and all treatments at 1 and 10 ng/
ml signiﬁ  cantly induced expression compared with untreated controls 
(p<0.05). #p<0.05 compared with effects of single treatments at 
each cytokine concentration, N=3. (B) Time course of induction of 
11β-HSD1 mRNA following treatment of MG-63 cells with IL-1β or 
IL-1β + dexamethasone. All treatments signiﬁ  cantly induced expression 
compared with time 0 (p<0.01). #p<0.05 compared with effects of 
single treatments at each time point, N=3.
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does not lead to the complete resolution of inﬂ  ammation. The 
reason for this failure is unclear, but the presence of cells within 
the joint that are resistant to locally produced glucocorticoids is 
a potential explanation.6 20 21
The mechanisms underlying periarticular bone loss in 
inﬂ  ammatory arthritis remain unclear. Increased bone resorp-
tion due to increased osteoclast formation has been proposed, 
and the pharmacological inhibition of bone resorption can pre-
vent bone loss in animal models.22 However, this bone loss 
is not accompanied by an expected compensatory increase 
in bone formation. We have hypothesised that this uncou-
pling of formation from resorption is due to the production 
of gluco  corticoids within periarticular osteoblasts or nearby 
synovium.5 6 The ﬁ  ndings in this study support this hypoth-
esis and also suggest that glucocorticoids generated within 
the synovium could increase glucocorticoid-generating capac-
ity in periarticular bone in the presence of proinﬂ  ammatory 
cytokines. It is also possible that glucocorticoids generated 
within osteoblasts could have effects on synovial ﬁ  broblasts or 
immune cells within the synovium.
How glucocorticoids potentiate the effects of proinﬂ  amma-
tory cytokines on 11β-HSD1 transcription remains unclear. 
The ﬁ  nding that adipocytes are responsive to glucocorticoid or 
cytokine induction of 11β-HSD1 expression but not the combi-
nation indicates that tissue-speciﬁ  c factors are important. The 
reason for the variation of induction across osteoblast differ-
entiation also needs to be determined. It is possible that the 
lack of effect during mid-differentiation is explained by the 
high expression of 11β-HSD1 at this stage. We have previously 
shown that induction across differentiation is mediated by the 
proximal promoter.14 It will be important to characterise the 
tissue speciﬁ  city of these effects given that many cell types 
express 11β-HSD1.11 23–25 Our results show clear heterogeneity 
of this effect across tissues.
The identiﬁ   cation of a powerful interaction between pro-
inﬂ  ammatory cytokines and glucocorticoids for the induction 
of glucocorticoid-generating capacity has implications for bone 
diseases. It may explain why patients with inﬂ  ammatory dis-
orders develop more bone loss with glucocorticoids than those 
without.26 The biological signiﬁ  cance of the synergistic induc-
tion of 11β-HSD1 is also unclear, but the dynamics of induction 
suggest that local glucocorticoid production will occur hours to 
days after exposure to inﬂ  ammation. This may therefore be a 
mechanism to downregulate excessive inﬂ  ammation (akin to 
the rise in cortisol levels due to hypothalamo–pituitary–adrenal 
axis activation with stress).27 The observation that only low 
glucocorticoid concentrations are required to induce 11β-HSD1 
synergistically may explain why even low-dose glucocorticoids 
are linked to bone loss in inﬂ  ammatory diseases.28 These obser-
vations also need to be considered when evaluating the clinical 
effects of 11β-HSD1 enzyme inhibitors.29 On the basis of this 
study some effects of these drugs may only become apparent 
in the presence of both inﬂ  ammation and the levels of gluco-
corticoids seen during stress.
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DISCUSSION
We found that the exposure of synovial fibroblasts or osteo-
blasts to both proinflammatory cytokines and glucocor-
ticoids dramatically increased glucocorticoid-generating 
capacity relative to each factor in isolation. This synergistic 
induction of glucocorticoid-generating capacity had impor-
tant functional consequences. This potentiation, rather than 
suppression, of localised inflammation-induced expression 
of 11β-HSD1 by glucocorticoids may be an endogenous 
mechanism to reduce synovitis. However, with persistent 
inflammation, the resulting tissue-specific elevation of glu-
cocorticoid generation is likely to contribute to periarticular 
bone loss in inflammatory joint disease, and could explain 
why inflammatory diseases sensitise bone to the effects of 
therapeutic glucocorticoids.
There are multiple interactions between pro-inﬂ  ammatory 
cytokines and glucocorticoids. In most situations glucocorti-
coids antagonise the actions and production of pro-inﬂ  amma-
tory cytokines through the inhibition of activator protein 1 or 
nuclear factor kappa B signalling pathways.10 Additive or syn-
ergistic interaction is less commonly reported.16–18 Synergistic 
interactions in these situations have been reported to be by 
effects on p38-mitogen-activated protein kinase, mitogen-ac-
tivated protein kinase phosphatase or increased mRNA stabil-
ity. A glucocorticoid–cytokine interaction has previously been 
reported for 11β-HSD1 in chorionic trophoblast cells.19 On the 
basis of promoter–reporter assays it was concluded that this 
effect was transcriptionally mediated by means of the proximal 
promoter.
Recent reports have demonstrated 11β-HSD1 expression in 
synovial ﬁ  broblasts in vitro and in vivo.4 6 20 Local generation 
of active glucocorticoids in patients with inﬂ  ammatory arthritis 
was demonstrated on the basis of synovial ﬂ  uid corticosteroid 
measurements, and this activity correlated with measures of 
inﬂ  ammation.6 This increase in local steroid generation might be 
aimed at resolving prolonged synovial inﬂ  ammation. It is possi-
ble that in transient synovitis, locally produced gluco  corticoids 
reduce inﬂ  ammation and hasten resolution. However, in rheu-
matoid arthritis, this increased generation of glucocorticoids 
Figure 5  Functional impact of 11β-hydroxysteroid dehydrogenase 
type 1 (11β-HSD1) synergism in primary synovial ﬁ  broblasts. The 
functional response to the synergistic induction of 11β-HSD1 activity 
by IL-1β and dexamethasone (DEX) was assessed in primary synovial 
ﬁ  broblasts. Cells were treated for 24 h with either IL-1β, dexamethasone 
or combined IL-1β and dexamethasone. Medium was then removed and 
cells were treated for a washout period of 24 h with unsupplemented 
medium. The functional impact of differences in 11β-HSD1 expression 
was then examined by treating cells for 24 h with cortisone (inactive 
substrate for 11β-HSD1). Data are shown as pg IL-6 produced during 
this 24 h incubation period. Data are based on cultures from three 
individuals.
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